Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director · Chief Executive Officer | September 22, 2026 | September 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date September 22, 2026 · Filed September 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,050,249 |
Ending reported balance
After 2026-09-22 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-22 · Sale · Disposed 1,000 · Balance 1,074,249 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F2: This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 2 · 2026-09-22 · Sale · Disposed 2,000 · Balance 1,072,249 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F3: This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 3 · 2026-09-22 · Sale · Disposed 9,300 · Balance 1,062,949 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F4: This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 4 · 2026-09-22 · Sale · Disposed 9,900 · Balance 1,053,049 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F5: This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 5 · 2026-09-22 · Sale · Disposed 2,800 · Balance 1,050,249 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F6: This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 27 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 27 F7: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 213,250 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 213,250 F8: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 71,644 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 71,644 F9: The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4: This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5: This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6: This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F7: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
F8: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F9: The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2021 Filed Feb 4, 2021 01:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 9,108 | $5.04 | $45,904.32 |
DisclosureSEC source: 0001209191-21-007563 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 889,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-21-002195 · doc4.xml · derivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,515 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · derivative.exercise_date: This option, originally for 250,000 shares, of which 135,485 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $141.91 | $28,382.00 |
DisclosureSEC source: 0001209191-21-002195 · doc4.xml · nonDerivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,468 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $141.61 to $142.21. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,523 | $140.83 | $214,486.07 |
DisclosureSEC source: 0001209191-21-002195 · doc4.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,668 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $140.54 to $141.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,277 | $139.91 | $878,233.27 |
DisclosureSEC source: 0001209191-21-002195 · doc4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882,191 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $139.49 to $140.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,000 | $139.08 | $278,160.20 |
DisclosureSEC source: 0001209191-21-002195 · doc4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 888,468 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $138.47 to $139.46. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001209191-21-002195 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 890,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 23:50 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 962 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-20-065099 · doc4.xml · derivative · entry 8 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,898 Underlying: Class A Common Stock · 962 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option, originally for 300,000 shares, of which 191,102 have been exercised, vested as to one-forty-eighth of the shares on October 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 23:50 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 2,667 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001209191-20-065099 · doc4.xml · derivative · entry 7 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 2,667 shares Expires 2026-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 23:50 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 962 | $1.20 | $1,154.40 |
DisclosureSEC source: 0001209191-20-065099 · doc4.xml · nonDerivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 23:50 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 2,667 | $1.07 | $2,853.69 |
DisclosureSEC source: 0001209191-20-065099 · doc4.xml · nonDerivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 879,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2020 Filed Dec 23, 2020 23:50 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065099 · doc4.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 876,839 Read SEC document |
| December 14, 2020 Filed Dec 23, 2020 23:50 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065099 · doc4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 89,960 F1 · ownership.nature: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee. Read SEC document |
| December 10, 2020 Filed Dec 23, 2020 23:50 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 104,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065099 · doc4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 104,960 F1 · ownership.nature: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee. Read SEC document |
| December 10, 2020 Filed Dec 23, 2020 23:50 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 104,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065099 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 861,839 Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 22:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 382 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-062588 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 966,799 Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-20-061714 · doc4.xml · derivative · entry 9 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,515 Underlying: Class A Common Stock · 3,750 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · derivative.exercise_date: This option, originally for 250,000 shares, of which 125,485 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 6,250 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-20-061714 · doc4.xml · derivative · entry 8 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,860 Underlying: Class A Common Stock · 6,250 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · derivative.exercise_date: This option, originally for 300,000 shares, of which 190,140 have been exercised, vested as to one-forty-eighth of the shares on October 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 333 | $153.84 | $51,230.02 |
DisclosureSEC source: 0001209191-20-061714 · doc4.xml · nonDerivative · entry 7 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 967,181 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $153.76 to $153.91. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,174 | $153.26 | $333,179.41 |
DisclosureSEC source: 0001209191-20-061714 · doc4.xml · nonDerivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 967,514 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $152.58 to $153.57. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,091 | $151.92 | $165,749.19 |
DisclosureSEC source: 0001209191-20-061714 · doc4.xml · nonDerivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 969,688 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $151.51 to $152.46. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,398 | $151.02 | $513,174.46 |
DisclosureSEC source: 0001209191-20-061714 · doc4.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 970,779 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $150.48 to $151.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,004 | $150.01 | $450,619.83 |
DisclosureSEC source: 0001209191-20-061714 · doc4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,177 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $149.46 to $150.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 3,750 | $5.04 | $18,900.00 |
DisclosureSEC source: 0001209191-20-061714 · doc4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 977,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 6,250 | $1.20 | $7,500.00 |
DisclosureSEC source: 0001209191-20-061714 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 02:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 2,924 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-20-057069 · doc4.xml · derivative · entry 14 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,265 Underlying: Class A Common Stock · 2,924 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F12 · derivative.exercise_date: This option, originally for 250,000 shares, of which 121,735 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 02:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $138.48 | $27,696.00 |
DisclosureSEC source: 0001209191-20-057069 · doc4.xml · nonDerivative · entry 11 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 967,181 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $138.20 to $138.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 02:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,524 | $137.50 | $209,548.78 |
DisclosureSEC source: 0001209191-20-057069 · doc4.xml · nonDerivative · entry 10 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 967,381 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $137.12 to $137.79. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 02:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,000 | $136.55 | $136,547.00 |
DisclosureSEC source: 0001209191-20-057069 · doc4.xml · nonDerivative · entry 9 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 968,905 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $136.09 to $136.92. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 02:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $135.54 | $27,107.00 |
DisclosureSEC source: 0001209191-20-057069 · doc4.xml · nonDerivative · entry 8 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 969,905 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $135.09 to $135.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 02:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 2,924 | $5.04 | $14,736.96 |
DisclosureSEC source: 0001209191-20-057069 · doc4.xml · nonDerivative · entry 7 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 970,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 02:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 826 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-20-057069 · doc4.xml · derivative · entry 13 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,189 Underlying: Class A Common Stock · 826 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F11 · derivative.exercise_date: This option, originally for 250,000 shares, of which 118,811 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 02:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 6,250 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-20-057069 · doc4.xml · derivative · entry 12 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,110 Underlying: Class A Common Stock · 6,250 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · derivative.exercise_date: This option, originally for 300,000 shares, of which 183,890 have been exercised, vested as to one-forty-eighth of the shares on October 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 02:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 900 | $138.54 | $124,686.00 |
DisclosureSEC source: 0001209191-20-057069 · doc4.xml · nonDerivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 967,181 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $137.88 to $139.23. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 02:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $137.10 | $68,552.00 |
DisclosureSEC source: 0001209191-20-057069 · doc4.xml · nonDerivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 968,081 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $136.85 to $137.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 02:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,052 | $136.13 | $551,586.60 |
DisclosureSEC source: 0001209191-20-057069 · doc4.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 968,581 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $135.855 to $136.84. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 02:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,624 | $135.45 | $219,978.43 |
DisclosureSEC source: 0001209191-20-057069 · doc4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 972,633 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $134.84 to $135.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 02:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 826 | $5.04 | $4,163.04 |
DisclosureSEC source: 0001209191-20-057069 · doc4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 02:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 6,250 | $1.20 | $7,500.00 |
DisclosureSEC source: 0001209191-20-057069 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-20-053577 · doc4.xml · derivative · entry 7 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,015 Underlying: Class A Common Stock · 3,750 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · derivative.exercise_date: This option, originally for 250,000 shares, of which 117,985 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 6,250 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-20-053577 · doc4.xml · derivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,360 Underlying: Class A Common Stock · 6,250 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · derivative.exercise_date: This option, originally for 300,000 shares, of which 177,640 have been exercised, vested as to one-forty-eighth of the shares on October 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,250 | $126.08 | $283,674.15 |
DisclosureSEC source: 0001209191-20-053577 · doc4.xml · nonDerivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 967,181 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $125.91 to $126.88. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,150 | $125.54 | $772,094.99 |
DisclosureSEC source: 0001209191-20-053577 · doc4.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 969,431 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $124.91 to $125.87. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,600 | $124.35 | $198,952.00 |
DisclosureSEC source: 0001209191-20-053577 · doc4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 975,581 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $123.86 to $124.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 3,750 | $5.04 | $18,900.00 |
DisclosureSEC source: 0001209191-20-053577 · doc4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 977,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 6,250 | $1.20 | $7,500.00 |
DisclosureSEC source: 0001209191-20-053577 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001209191-20-049523 · doc4.xml · derivative · entry 10 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,667 Underlying: Class A Common Stock · 14,000 shares Expires 2026-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This option exercise was not effected pursuant to a Rule 10b5-1 trading plan. F10 · derivative.exercise_date: This option, originally for 200,000 shares, of which 197,333 have been exercised, vested as to one-fourth of the shares on August 1, 2017, and one forty-eighth of the shares subject to the option vested each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 7,360 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-20-049523 · doc4.xml · derivative · entry 9 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,765 Underlying: Class A Common Stock · 7,360 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · derivative.exercise_date: This option, originally for 250,000 shares, of which 114,235 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 2,640 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-20-049523 · doc4.xml · derivative · entry 8 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,610 Underlying: Class A Common Stock · 2,640 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · derivative.exercise_date: This option, originally for 300,000 shares, of which 171,390 have been exercised, vested as to one-forty-eighth of the shares on October 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $115.53 | $23,105.00 |
DisclosureSEC source: 0001209191-20-049523 · doc4.xml · nonDerivative · entry 7 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 967,181 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $115.46 to $115.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.